Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
10 participants
INTERVENTIONAL
2019-06-21
2024-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Behavioral Pharmacology of THC and Alpha-pinene
NCT04130633
Behavioral Pharmacology of THC and D-limonene
NCT03609853
Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia
NCT03679949
Influence of Δ9-tetrahydrocannabinol (THC) on Oxycodone Induced Ventilatory Depression in Healthy Volunteers
NCT05235503
Effects of Various Cannabis Strains on Perceptual, Subjective and Objective Use Outcomes
NCT07214155
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vaporized Marijuana
Participants will receive non-therapeutic, experimental doses of active vaporized marijuana. Active marijuana will be administered once per session and will be administered via a vaporizer.
Vaporized Marijuana
Active Marijuana administered through vaporizer
Placebo
Experimental, non-therapeutic administration of inactive opioid or marijuana dose(s)
Opioid Agonist
Participants will receive non-therapeutic, experimental doses of an active opioid agonist. Active opioid agonist will be administered once per session and will be administered intranasally (snorting).
Opioid Agonist
Active Opioid Agonist administered intranasally
Placebo
Experimental, non-therapeutic administration of inactive opioid or marijuana dose(s)
Opioid Agonist/Marijuana Combination
Participants will receive non-therapeutic, experimental doses of active opioid in combination with non-therapeutic, experimental doses of active vaporized marijuana. Opioid and marijuana doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer.
Vaporized Marijuana
Active Marijuana administered through vaporizer
Opioid Agonist
Active Opioid Agonist administered intranasally
Placebo
Participants will receive non-therapeutic, experimental doses of placebo. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer.
Placebo
Experimental, non-therapeutic administration of inactive opioid or marijuana dose(s)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vaporized Marijuana
Active Marijuana administered through vaporizer
Opioid Agonist
Active Opioid Agonist administered intranasally
Placebo
Experimental, non-therapeutic administration of inactive opioid or marijuana dose(s)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current non-medical use of opioids and marijuana
Exclusion Criteria
* Seeking treatment for drug use
* Significant medical problems
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Shanna Babalonis, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shanna Babalonis, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shanna Babalonis, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Kentucky
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kentucky
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
45017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.